Beta Bionics Faces Securities Fraud Lawsuit After Stock Plunge

Beta Bionics, Inc. is the subject of a securities fraud class action lawsuit filed on behalf of investors who allege the company misled them about the safety, efficacy, and commercial success of its iLet medical device. The lawsuit was initiated after the company's stock price declined by more than 37%.

The class action is pending in the U.S. District Court for the Central District of California. Investors have until November 3, 2026, to petition the court to be appointed lead plaintiff. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Beta Bionics offers an automated insulin delivery system for diabetes treatment, known as the iLet Bionic Pancreas. The device is designed to autonomously manage insulin doses without requiring manual carbohydrate counting or correction calculations by the user. The company had reportedly promoted the iLet's clinical outcomes and positive reception from healthcare professionals.

However, in June 2025, the U.S. Food and Drug Administration (FDA) issued Beta Bionics a Form 483 detailing over 18,000 unreported complaints from iLet users since its launch. The complaints allegedly concerned cases of life-threatening hypoglycemia due to the device's aggressive insulin dosing algorithm, which the company failed to investigate or address.

The stock price decline began on January 8, 2026, when Beta Bionics announced that new patient starts for the iLet missed analyst estimates by nearly 10%, causing a 37% drop. Subsequently, on February 24, 2026, the FDA publicly released a warning letter citing the company's failure to report hypoglycemia instances caused by iLet malfunctions, leading to a further decrease in stock value.